Granisetron vs ondansetron:: is it a question of duration of 5-HT3 receptor blockade?

被引：16

作者：

Blower, P ^{[1
]}

Aapro, M

机构：

[1] Poole House, Halstead CO9 4HP, Essex, England

[2] Clin Genolier, CH-1272 Genolier, Switzerland

来源：

BRITISH JOURNAL OF CANCER | 2002年 / 86卷 / 10期

关键词：

D O I：

10.1038/sj.bjc.6600313

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1662 / 1663

页数：2

共 17 条

[1] STRATIFIED, RANDOMIZED, DOUBLE-BLIND COMPARISON OF INTRAVENOUS ONDANSETRON ADMINISTERED AS A MULTIPLE-DOSE REGIMEN VERSUS 2 SINGLE-DOSE REGIMENS IN THE PREVENTION OF CISPLATIN-INDUCED NAUSEA AND VOMITING [J].

BECK, TM ;

HESKETH, PJ ;

MADAJEWICZ, S ;

NAVARI, RM ;

PENDERGRASS, K ;

LESTER, EP ;

KISH, JA ;

MURPHY, WK ;

HAINSWORTH, JD ;

GANDARA, DR ;

BRICKER, LJ ;

KELLER, AM ;

MORTIMER, J ;

GALVIN, DV ;

HOUSE, KW ;

BRYSON, JC .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (12) :1969-1975

[2] Use of granisetron in patients refractory to previous treatment with antiemetics [J].

Carmichael, J ;

Keizer, HJ ;

Cupissol, D ;

Milliez, J ;

Scheidel, P ;

Schindler, AE .

ANTI-CANCER DRUGS, 1998, 9 (05) :381-385

[3]

CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45

[4]

COOPER SM, 1988, BRIT J CLIN PHARMACO, V25, pP106

[5]

Doherty K M, 1999, Clin J Oncol Nurs, V3, P113

[6]

EWIT R, 2001, BRIT J CANCER, V85, P1099

[7] Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy [J].

Fauser, AA ;

Duclos, B ;

Chemaissani, A ;

DelFavero, A ;

Cognetti, F ;

DiazRubio, E ;

CortesFunes, H ;

Conte, PF ;

Dressler, H .

EUROPEAN JOURNAL OF CANCER, 1996, 32A (09) :1523-1529

[8] Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy -: Dose, schedule, and route of administration [J].

Gandara, DR ;

Roila, F ;

Warr, D ;

Edelman, MJ ;

Perez, EA ;

Gralla, RJ .

SUPPORTIVE CARE IN CANCER, 1998, 6 (03) :237-243

[9]

GRUNBERG SM, 1992, SEMIN ONCOL, V19, P16

[10] BRL-46470 POTENTLY ANTAGONIZES NEURAL RESPONSES ACTIVATED BY 5-HT(3) RECEPTORS [J].

NEWBERRY, NR ;

WATKINS, CJ ;

SPROSEN, TS ;

BLACKBURN, TP ;

GRAHAMESMITH, DG ;

LESLIE, RA .

NEUROPHARMACOLOGY, 1993, 32 (08) :729-735

← 1 2 →